Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :22693444
Publication Date : //

Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.


Sexual transmission of human immunodeficiency virus type 1 (HIV-1) most often results from productive infection by a single transmitted/founder (T/F) virus, indicating a stringent mucosal bottleneck. Understanding the viral traits that overcome this bottleneck could have important implications for HIV-1 vaccine design and other prevention strategies. Most T/F viruses use CCR5 to infect target cells and some encode envelope glycoproteins (Envs) that contain fewer potential N-linked glycosylation sites and shorter V1/V2 variable loops than Envs from chronic viruses. Moreover, it has been reported that the gp120 subunits of certain transmitted Envs bind to the gut-homing integrin α4β7, possibly enhancing virus entry and cell-to-cell spread. Here we sought to determine whether subtype C T/F viruses, which are responsible for the majority of new HIV-1 infections worldwide, share biological properties that increase their transmission fitness, including preferential α4β7 engagement. Using single genome amplification, we generated panels of both T/F (n = 20) and chronic (n = 20) Env constructs as well as full-length T/F (n = 6) and chronic (n = 4) infectious molecular clones (IMCs). We found that T/F and chronic control Envs were indistinguishable in the efficiency with which they used CD4 and CCR5. Both groups of Envs also exhibited the same CD4+ T cell subset tropism and showed similar sensitivity to neutralization by CD4 binding site (CD4bs) antibodies. Finally, saturating concentrations of anti-α4β7 antibodies failed to inhibit infection and replication of T/F as well as chronic control viruses, although the growth of the tissue culture-adapted strain SF162 was modestly impaired. These results indicate that the population bottleneck associated with mucosal HIV-1 acquisition is not due to the selection of T/F viruses that use α4β7, CD4 or CCR5 more efficiently.

Authors : Parrish Nicholas F , Wilen Craig B , Banks Lauren B , Iyer Shilpa S , Pfaff Jennifer M , Salazar-Gonzalez Jesus F , Salazar Maria G , Decker Julie M , Parrish Erica H , Berg Anna , Hopper Jennifer , Hora Bhavna , Kumar Amit , Mahlokozera Tatenda , Yuan Sally , Coleman Charl , Vermeulen Marion , Ding Haitao , Ochsenbauer Christina , Tilton John C , Permar Sallie R , Kappes John C , Betts Michael R , Busch Michael P , Gao Feng , Montefiori David , Haynes Barton F , Shaw George M , Hahn Beatrice H , Doms Robert W ,

Related products :

Catalog number Product name Quantity
P-CCR5 Rabbit CCR5 Antibody Blocking Peptide 250
31-062 DOK1 is constitutively tyrosine phosphorylated in hematopoietic progenitors isolated from chronic myelogenous leukemia (CML) patients in the chronic phase. It may be a critical substrate for p210 (bcr 0.05 mg
31-076 DOK2 is constitutively tyrosine phosphorylated in hematopoietic progenitors isolated from chronic myelogenous leukemia (CML) patients in the chronic phase. It may be a critical substrate for p210 (bcr 0.05 mg
20-272-190195 CCR5 - Mouse monoclonal [45523.111] to CCR5; C-C CKR-5; CC-CKR-5; CCR-5; CCR5; HIV-1 fusion coreceptor; CHEMR13; CD195 antigen Monoclonal 0.1 mg
18-272-196985 CCR5 - Goat polyclonal to CCR5; C-C CKR-5; CC-CKR-5; CCR-5; CCR5; HIV-1 fusion coreceptor; CHEMR13; CD195 antigen Polyclonal 0.1 mg
20-272-190540 CCR5 - Rat monoclonal [HEK _ 1 _ 85a] to CCR5; C-C CKR-5; CC-CKR-5; CCR-5; CCR5; HIV-1 fusion coreceptor; CHEMR13; CD195 antigen Monoclonal 0.1 mg
33R-8508 CCR5 Blocking Peptide, Blocking Peptides 100 ug
orb61265 MK-4827 MK-4827 displays excellent PARP 1 and 2 inhibition with IC50 = 3.8 and 2.1 nM, resp., and in a whole cell assay, it inhibited PARP activity with EC50 = 4 nM and inhibited proliferation of canc 5 mg
25-180 Retinoid X receptors (RXRs) and retinoic acid receptors (RARs), are nuclear receptors that mediate the biological effects of retinoids by their involvement in retinoic acid-mediated gene activation. T 0.05 mg
EIAAB30312 CGIP1,CGI-PDE B,CGIPDE1,cGMP-inhibited 3',5'-cyclic phosphodiesterase B,Cyclic GMP-inhibited phosphodiesterase B,Homo sapiens,Human,PDE3B
EIAAB30310 CGI-PDE B,CGIPDE1,cGMP-inhibited 3',5'-cyclic phosphodiesterase B,Cyclic GMP-inhibited phosphodiesterase B,Mouse,Mus musculus,Pde3b
EIAAB30311 CGI-PDE B,CGIPDE1,cGMP-inhibited 3',5'-cyclic phosphodiesterase B,Cyclic GMP-inhibited phosphodiesterase B,Pde3b,Rat,Rattus norvegicus
EIAAB30309 CGI-PDE A,cGMP-inhibited 3',5'-cyclic phosphodiesterase A,Cyclic GMP-inhibited phosphodiesterase A,Homo sapiens,Human,PDE3A
20-272-190541 CCR5 ( FITC ) - Rat monoclonal [HEK _ 1 _ 85a] to CCR5 ( FITC ); C-C CKR-5; CC-CKR-5; CCR-5; CCR5; HIV-1 fusion coreceptor; CHEMR13; CD195 antigen Monoclonal 0.05 mg
EIAAB30307 CGI-PDE A,cGMP-inhibited 3',5'-cyclic phosphodiesterase A,Cyclic GMP-inhibited phosphodiesterase A,Mouse,Mus musculus,Pde3a
EIAAB30308 CGI-PDE A,cGMP-inhibited 3',5'-cyclic phosphodiesterase A,Cyclic GMP-inhibited phosphodiesterase A,Pde3a,Rat,Rattus norvegicus
EIAAB06201 Bos taurus,Bovine,C-C chemokine receptor type 5,C-C CKR-5,CC-CKR-5,CCR5,CCR5,CCR-5,CMKBR5
LF-MA41735 Anti-CCR5 (HEK_1_85a), Rat Monoclonal to CCR5, Isotype IgG2a, Host Rat 50
18-783-76425 RABBIT ANTI HUMAN CD195 (CCR5) - CCR5; Polyclonal 0.1 mg
10R-6503 CCR5 antibody, Monoclonal Antibodies, Host Hamster, Isotype IgG, Clone HM-CCR5 100 ug
10R-6503 CCR5 antibody, Monoclonal Antibodies, Host Hamster, Isotype IgG, Clone HM-CCR5 50 ug
CCR5-501AP chemokine (C-C) receptor 5 WB control: PC-CCR5 Host: Rabbit Affinity purifed 100-150ul
CCR5-501AP CCR5-FITC conjugate Polyclonal Antibody Host Species: Rabbit 200ul
CCR5-501AP CCR5-Biotin conjugate Polyclonal Antibody Host Species: Rabbit 200ul
CCR5-501AP PC-CCR5 (WB control) chemokine (C-C) receptor 5 Immunogen: peptide Host: Rabbit 100-150ul


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur